pharma · Rectal Cancer · Fanconi Anemia · RCKT
Rocket Pharmaceuticals
Rocket Pharmaceuticals B.V.
Rocket Pharmaceuticals clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 9 Cedarbrook Dr, Cranbury, New Jersey 08512, US
- Founded
- 2015
- Employees
- 226
- Programs
- 11
- Drugs
- 10
- Patents
- 1
Rocket Pharmaceuticals projects
4 ClinicalTrials.gov programs sponsored by Rocket Pharmaceuticals.
Rocket Pharmaceuticals has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Filgrastim
Rocket Pharmaceuticals B.V.
Fanconi Anemia
1 trial -
RP-A601
Rocket Pharmaceuticals B.V.
PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
1 trial -
RP-A701-0125
Rocket Pharmaceuticals B.V.
Dilated Cardiomyopathy (DCM)
1 trial -
RP-L401
Rocket Pharmaceuticals B.V.
Infantile Malignant Osteopetrosis
1 trial
Frequently asked questions
How many clinical projects does Rocket Pharmaceuticals have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.